Breaking News

Mayne Pharma Appoints President

By Kristin Brooks | January 28, 2014

Cross to spearhead investments in Metrics ops

Stefan Cross has been appointed president of Mayne Pharma USA. Mr. Cross is responsible for leading the company’s existing business operations in the U.S., as well as spearheading new business development initiatives. Mr. Cross succeeds Phil Hodges, who founded Metrics, Inc. and has recently retired as president of the company. Mr. Hodges serves on the board of directors of Mayne Pharma Group.
Mr. Cross’ responsibilities also include managing Mayne Pharma’s North American contract services subsidiary, Metrics, and growing its solid oral dose formulation development and analytical support services. The company also plans to make significant investments in Metrics’ fast-track, proof-of-concept, and first-time-in-man programs, potent and cytotoxic product handling, and clinical trial material manufacturing services. He will also oversee the expansion of Mayne Pharma USA’s pharmaceutical products division, which now markets more than 20 products and has 20 products under development with 10 ANDAs filed with the FDA. Mr. Cross will focus on expanding the U.S. product portfolio through both organic development and acquisitions.
Mr. Cross brings more than 20 years of industry experience. He previously served as Mayne Pharma’s vice president of business and corporate development, and played a key role in the global commercialization of the company’s SUBACAP anti-fungal product. He has been extensively involved in integrating Metrics with Mayne Pharma, and in executing the company’s business strategy in Australia and the U.S.
“Stefan has an impressive track record of success in the pharmaceutical industry and will add tremendous value to our U.S. business,” said Scott Richards, chief executive officer of Mayne Pharma. “His breadth of experience covers commercial operations, marketing, product licensing, business strategy and M&A. I look forward to accelerating the growth of our U.S. businesses with Stefan’s support and leadership.”
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)